ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 94

NGS Panel for the Detection of Monogenic SLE in Children: Initial Results

Alexandre Belot1, Gillian Rice2, Anne-Laure Mathieu1, Brigitte Bader-Meunier3, Thierry Walzer1, Tracy A. Briggs2, James O'Sullivan4, Simon Wiliams5, Michael W. Beresford6, Yanick Crow2,7 and GENIAL Investigators, UK JSLE Study Group, 1INSERM U1111, Lyon, France, 2Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 3Pediatric Rheumatology & Immunology, Necker hospital, Imagine Institution, Paris, France, 4University of Manchester, Manchester, United Kingdom, 5University of Manchester, Manchester, France, 6Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 7Neuroinflammation, Institut Imagine, Paris, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Genetic disorders, genetics and pediatric rheumatology, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Genetics, Genomics and Proteomics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Next generation sequencing (NGS) represents a revolution in the field of molecular medicine, and offers a new approach to deciphering the pathogenesis of complex diseases. Paediatric-onset SLE (pSLE) is a very rare and more severe phenotype than its adult-onset counterpart, and is possibly associated with a greater contribution of genetic aetiological factors. A few monogenic causes of SLE have been described, including: complement deficiencies, defects of apoptosis and the so-called interferonopathies. The frequency of these Mendelian subtypes in a large cohort of pSLE has not been assessed previously.

Methods:

We designed an NGS panel comprising 200 genes including proven disease-associated as well as prospective candidate genes, and analysed 85 children under 11 years of age who fulfilled ACR criteria for SLE. As a first step, we focussed on rare (ExAC database frequency of < 1% for homozygous variants and < 0.01% for heterozygous variants) null / frameshift variants, and missense substitutions predicted in silico as damaging by both SIFT and POLYPHEN.

Results:

We identified three patients with biallelic mutations in genes of the complement pathway – one with a homozygous missense variant (p.Gly164Ser) and one with compound heterozygous variants (p.Gly164Ser/p.Leu41CysfsTer97) in C1QC, and one with a homozygous frameshift variant (p.Ile15AsnfsTer7) in C1QA. Four further patients harboured heterozygous variants (in C1QC, C2, C5 and C9) which were predicted as pathogenic. Copy number variant analysis in these genes has not yet been undertaken. A TREX1 p.Ser82LeufsTer9 variant, previously observed in a patient with Aicardi-Goutières syndrome, was identified in one patient in combination with a missense variant of unknown significance. One patient carried a heterozygous variant in ACP5 – predicted as pathogenic by in silico analysis but not seen previously in SPENCD. In total, 11 patients harboured heterozygous rare variants in 2 or 3 panel genes (8 and 3 patients respectively). No likely pathogenic variants were identified in DNASE1, DNASE1L3 or PRKCD.

Conclusion:

This first-step analysis of candidate gene variants in a population of 85 pSLE patients revealed three cases of C1Q deficiency – associated with a 1 in 4 risk of recurrence, and which had not been diagnosed previously. The significance of heterozygous variants in other genes is difficult to determine at this stage. The association of 2 / 3 very rare heterozygous variants in a single patient raises the possibility of an oligogenic burden in the pathogenesis of pSLE. Functional experiments are mandatory to understand the impact of these rare variants. Future work will also involve increasing the number of patients analysed, and consideration of intronic and splicing variants. However, we already conclude that an NGS panel approach can diagnose unappreciated monogenic forms of pSLE.


Disclosure: A. Belot, None; G. Rice, None; A. L. Mathieu, None; B. Bader-Meunier, None; T. Walzer, None; T. A. Briggs, None; J. O'Sullivan, None; S. Wiliams, None; M. W. Beresford, None; Y. Crow, None.

To cite this abstract in AMA style:

Belot A, Rice G, Mathieu AL, Bader-Meunier B, Walzer T, Briggs TA, O'Sullivan J, Wiliams S, Beresford MW, Crow Y. NGS Panel for the Detection of Monogenic SLE in Children: Initial Results [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/ngs-panel-for-the-detection-of-monogenic-sle-in-children-initial-results/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ngs-panel-for-the-detection-of-monogenic-sle-in-children-initial-results/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology